Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management (Wegovy, employer plans with weight-management benefit) | Covered with PA |
| Obesity / chronic weight management (Zepbound, employer plans with weight-management benefit) | Covered with PA |
| Cardiovascular risk reduction (Wegovy, SELECT indication) | Covered with PA |
Plan type: Commercial employer-sponsored plans (fully insured and self-funded). Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. Roughly 60 percent of UHC commercial members are in self-funded employer plans. The employer bears the drug cost and independently decides whether to include anti-obesity medications in the benefit design. Many employers exclude GLP-1s for weight loss entirely, even when the UHC standard commercial formulary would cover them. The only way to confirm your coverage is to call the member services number on your card and ask whether your specific plan covers Wegovy or Zepbound for weight management. OptumRx is the pharmacy benefit manager.
Coverage by indication
| BMI threshold | BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, or obstructive sleep apnea) |
| Step therapy | No step therapy through phentermine or orlistat is required on most commercial plans. UHC eliminated this requirement for most obesity PAs in 2025. Six months of documented comprehensive lifestyle intervention is required. |
| Authorization length | 5 months initial, 12 months continuation |
What the prior authorization needs:
- Your employer plan must include the weight-management drug benefit
- BMI within the accepted threshold
- Six months of documented lifestyle intervention with specific program descriptions, not vague references to diet and exercise
- Comorbidity documentation if BMI is 27 to 29.9
- Prescriber attestation of ongoing lifestyle counseling alongside medication
Source: UnitedHealthcare Pharmacy, PA Notification Weight Loss (2026 UnitedHealthcare Services Inc.). Official payer PA notification document (public URL confirmed; framework cross-checked against the UHC provider portal and independent formulary analysis). Verified June 12, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
| BMI threshold | BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, or obstructive sleep apnea) |
| Step therapy | No step therapy through non-GLP-1 agents required on most plans. Six months of documented comprehensive lifestyle intervention required. OptumRx applies the documentation requirement strictly. |
| Authorization length | 6 months initial, 12 months continuation |
What the prior authorization needs:
- Your employer plan must include the weight-management drug benefit
- BMI within the accepted threshold
- Six months of documented lifestyle intervention with specific program name and dates of participation
- Comorbidity documentation if BMI is 27 to 29.9
- Prescriber attestation of ongoing diet and exercise counseling
Source: UnitedHealthcare Pharmacy, PA Notification Weight Loss (2026 UnitedHealthcare Services Inc.). Official payer PA notification document (public URL confirmed; Zepbound PA duration cross-checked against OptumRx commercial PA criteria and independent formulary analysis). Verified June 12, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
| BMI threshold | BMI 27 or higher with established cardiovascular disease |
| Cardiovascular criteria | Established cardiovascular disease per the SELECT trial enrollment criteria: prior heart attack, prior stroke, or symptomatic peripheral arterial disease. This pathway is separate from the obesity indication and not subject to the employer weight-management benefit election. |
| Step therapy | No step therapy required for the cardiovascular indication. |
What the prior authorization needs:
- Established cardiovascular disease documented with prior heart attack, stroke, or peripheral arterial disease
- BMI 27 or higher
- Prior authorization required
Source: UnitedHealthcare Pharmacy, PA Notification Weight Loss (2026 UnitedHealthcare Services Inc.). Official payer PA notification document (public URL confirmed; SELECT-indication pathway confirmed via UHC coverage update and secondary analysis). Verified June 12, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it.
- Start with the UnitedHealthcare prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash-pay options in the cost guide and the cheapest legitimate programs.
Frequently asked questions
Does UnitedHealthcare cover Wegovy for weight loss?
UnitedHealthcare's standard commercial criteria cover Wegovy for obesity and chronic weight management with prior authorization, for members whose employer plan includes the weight-management drug benefit. The BMI requirement is 30 or higher, or 27 or higher with a weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, or sleep apnea). Six months of documented lifestyle intervention is required. About 60 percent of UHC members are in self-funded employer plans where the employer sets the drug benefit, so coverage is not guaranteed simply because the UHC standard formulary allows it. Per the UHC PA Notification Weight Loss document, verified June 2026.
Does UnitedHealthcare cover Zepbound?
UnitedHealthcare covers Zepbound for obesity with prior authorization under the same standard commercial criteria as Wegovy, when your employer plan includes the weight-management benefit. The BMI threshold is 30 or higher, or 27 or higher with a qualifying comorbidity. Six months of structured lifestyle intervention documentation is required, and OptumRx applies this requirement strictly: vague documentation is more likely to be denied than specific program descriptions. Zepbound is also covered as a separate pathway for moderate-to-severe obstructive sleep apnea (BMI 27 or higher, AHI 15 or higher confirmed by sleep study), independent of the weight-management benefit election. Per the UHC PA Notification Weight Loss and OptumRx commercial PA documents, verified June 2026.
What BMI does UnitedHealthcare require for GLP-1 coverage?
UnitedHealthcare's standard prior-authorization criteria require BMI 30 or higher for obesity without a comorbidity, or BMI 27 or higher with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea. These thresholds apply to both Wegovy and Zepbound under the commercial weight-management PA. Zepbound's separate OSA pathway requires BMI 27 or higher with moderate-to-severe sleep apnea confirmed by a sleep study, regardless of whether the employer elected the weight-management drug benefit.
Why might UnitedHealthcare deny Wegovy even if I meet the criteria?
The most common reason is that your employer's self-funded plan has excluded the weight-management drug benefit, even though UHC's standard formulary would cover you. Beyond that: vague lifestyle-intervention documentation (writing 'patient has tried diet and exercise' rather than describing a specific program with dates tends to get denied at OptumRx); failure to meet the BMI threshold; or missing comorbidity documentation when BMI is 27 to 29.9. UHC eliminated mandatory step therapy through phentermine or orlistat for most commercial obesity PAs in 2025, so that is no longer a barrier on most plans. If your employer plan excluded the benefit, the only path is a formulary exception or switching plans.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
